Study of Brain and Spinal Cord Tumor Growth and Cyst Development in Patients With Von Hippel Lindau Disease

StatusActive, Not Recruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 322 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. 34 versions Re-verified since May 10, 2025, no change to tracked fieldsv289-v322
  2. Minor Eligibility criteria shortened, about 15 words
    • Study description shortened, about 1 word
    v288
  3. 15 versions Re-verified since Nov 28, 2024, no change to tracked fieldsv273-v287
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to learn more about the growth of brain and spinal cord tumors and cysts that develop in association with them in patients with von Hippel-Lindau disease. It will examine how fast the tumors grow and try to determine what factors (for example, puberty , pregnancy, menopause, blood proteins, etc.) affect their growth. Patients between the ages of 8 and 75 years who are enrolled in NIH s study of von Hippel-Lindau disease may be eligible for this 5-year study. Participants will have magnetic resonance imaging (MRI) of the brain and spinal cord and a thorough neurological history and examination at the start of the study. A blood sample will be taken for analysis of factors (hormones or other proteins) that may predict tumor growth. Follow-up clinic visits every 6 months will include a physical and neurological examination, blood tests, and MRI scans of the brain and spine. If symptoms or tumor growth requires more frequent follow-up, scans will be done at 3-month intervals. Surgical removal of brain and spinal cord tumors is currently the treatment of choice when these lesions cause neurological problems. A better understanding of which tumors are likely to grow and which will remain stable may help guide physicians in treatment decisions and avoid unnecessary procedures.
Trial Details
NCT Number NCT00005902
Lead Sponsor National Institute of Neurological Disorders and Stroke (NINDS)
Conditions
(from sponsor)
Hemangioblastoma, Hippel Lindau Disease
Related terms Cysts, Hemangioblastoma, von Hippel-Lindau Disease
Enrollment 250 participants
Start Date
Updated on ClinicalTrials.gov